Type 2 Diabetes

Apart from Sotagliflozin’s use in the treatment of people with type 2, SGLT-1 and SGLT-2 inhibitors effects on type 1 currently being explored.

The value of self-monitoring of blood glucose (SMBG) levels in patients with non-insulin-treated type 2 diabetes has been debated over the years.

The Endocrinologic and Metabolic Drugs Advisory Committee also voted 19-0 that the drug's use in type 2 diabetes patients did not result in excess cardiovascular risk.

However, in 2016, Novo Nordisk halted the development of their basal oral insulin tablet.

The DEVOTE trial compared cardiovascular safety in two basal insulins; insulin degludec was found to have additional benefits.

Results from two ODYSSEY studies indicate the favorable lipid lowering effects of Alirocumab, a PCSK9 inhibitor, in type 2 diabetes patients can potentially reduce the risk of cardiovascular disease.

In this week's Homerun Slides, a summary of the clinical trials assessing the impact of intensive therapy in type 2 diabetes.

New study shows lower risk for poor cardiovascular outcomes for T2 patients on glucagonlike peptide-1 receptor agonists.

Results determined for 3-year study of liraglutide versus placebo diabetes risk reduction and weight management in individuals with prediabetes.

Study focused on type 2 diabetes patients who initiate metformin.